A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BCX4430
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
This is a 2-part, first-in-human dose-ranging study to evaluate the safety, tolerability and
pharmacokinetics of escalating doses of BCX4430 administered via intramuscular (IM) injection
in healthy subjects. In part 1, subjects will receive a single dose of BCX4430; in part 2
subjects will receive BCX4430 for 7 days.
Phase:
Phase 1
Details
Lead Sponsor:
BioCryst Pharmaceuticals
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)